Cardiovascular disease and heritability of the prothrombotic state

Blood Reviews

Volumn 23, Issue 2, 2009, Pages 67-78

  Ajjan, R A ^a   Ariens R A S ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Cardiovascular disease; Coagulation; Fibrin; Fibrinolysis; Genetics; Thrombosis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 7; CLOPIDOGREL; FIBRIC ACID DERIVATIVE; FIBRIN; FIBRINOGEN; GLICLAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX METALLOPROTEINASE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; ATHEROTHROMBOSIS; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIFESTYLE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THROMBOGENESIS; THROMBOSIS;

BLOOD COAGULATION; CARDIOVASCULAR DISEASES; HUMANS; THROMBOSIS;

EID: 61349157950     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2008.07.001     Document Type: Article

References (183)

1. Badimon L., Badimon J.J., Vilahur G., Segales E., and Llorente V. Pathogenesis of the acute coronary syndromes and therapeutic implications. Pathophysiol Haemost Thromb 32 5-6 (2002) 225-231
2. Bouma B.N., and Mosnier L.O. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol Haemost Thromb 33 5-6 (2003) 375-381
3. Norris L.A. Blood coagulation. Best Pract Res Clin Obstet Gynaecol 17 3 (2003) 369-383
4. Heemskerk J.W., Bevers E.M., and Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 88 2 (2002) 186-193
5. Monroe D.M., Hoffman M., and Roberts H.R. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 22 9 (2002) 1381-1389
6. Bennett J.S., and Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 64 5 (1979) 1393-1401
7. Greenberg C.S., Lai T.S., Ariëns R.A.S., Weisel J.W., and Grant P.J. Biology and disorders of fibrinogen and factor XIII. In: Handin R.I., Lux S.E., and Stossel T.P. (Eds). Blood-Principles and Practice of Hematology (2001), Lippincott Williams & Wilkins 1225-1248
8. Litvinov R.I., Gorkun O.V., Galanakis D.K., Yakovlev S., Medved L., Shuman H., et al. Polymerization of fibrin: direct observation and quantification of individual B:b knob-hole interactions. Blood 109 1 (2007) 130-138
9. Weisel J.W. Fibrinogen and fibrin. Adv Protein Chem 70 (2005) 247-299
10. Cesarman-Maus G., and Hajjar K.A. Molecular mechanisms of fibrinolysis. Br J Haematol 129 3 (2005) 307-321
11. Merlini P.A., Bauer K.A., Oltrona L., et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 90 1 (1994) 61-68
12. Gulba D.C., Barthels M., Reil G.H., and Lichtlen P.R. Thrombin/antithrombin-III complex level as early predictor of reocclusion after successful thrombolysis. Lancet 2 8602 (1988) 97
13. Bounameaux H., Cirafici P., de Moerloose P., et al. Measurement of D-dimer in plasma as diagnostic aid in suspected pulmonary embolism. Lancet 337 8735 (1991) 196-200
14. van der P., Buller H.R., ten Cate H., et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. New Engl J Med 322 23 (1990) 1622-1627
15. Ariëns R.A., de Lange M., Snieder H., Boothby M., Spector T.D., and Grant P.J. Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. Lancet 359 9307 (2002) 667-671
16. Rosendaal F.R., and Bovill E.G. Heritability of clotting factors and the revival of the prothrombotic state. Lancet 359 9307 (2002) 638-639
17. Vossen C.Y., Hasstedt S.J., Rosendaal F.R., et al. Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C-deficient family. J Thromb Haemost 2 2 (2004) 242-247
18. Anderson T.J. Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Fail Rev 8 1 (2003) 71-86
19. Blann A.D. Assessment of endothelial dysfunction: focus on atherothrombotic disease. Pathophysiol Haemost Thromb 33 5-6 (2003) 256-261
20. Davignon J., and Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 109 23 Suppl 1 (2004) III27-III32
21. Newby A.C. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 85 1 (2005) 1-31
22. Tousoulis D., Davies G., Stefanadis C., Toutouzas P., and Ambrose J.A. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 89 9 (2003) 993-997
23. Mach F., Schonbeck U., Bonnefoy J.Y., Pober J.S., and Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 96 2 (1997) 396-399
24. Miller D.L., Yaron R., and Yellin M.J. CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J Leukoc Biol 63 3 (1998) 373-379
25. Fukudome K., and Esmon C.T. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 269 42 (1994) 26486-26491
26. Archipoff G., Beretz A., Freyssinet J.M., Klein-Soyer C., Brisson C., and Cazenave J.P. Heterogeneous regulation of constitutive thrombomodulin or inducible tissue-factor activities on the surface of human saphenous-vein endothelial cells in culture following stimulation by interleukin-1, tumour necrosis factor, thrombin or phorbol ester. Biochem J 273 Pt 3 (1991) 679-684
27. Esmon C.T. The impact of the inflammatory response on coagulation. Thromb Res 114 5-6 (2004) 321-327
28. Rosenson R.S., and Koenig W. Utility of inflammatory markers in the management of coronary artery disease. Am J Cardiol 92 1A (2003) 10i-18i
29. Sturn D.H., Kaneider N.C., Feistritzer C., Djanani A., Fukudome K., and Wiedermann C.J. Expression and function of the endothelial protein C receptor in human neutrophils. Blood 102 4 (2003) 1499-1505
30. Conway E.M., Van de W.M., Pollefeyt S., et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 196 5 (2002) 565-577
31. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 61 3 (2004) 498-511
32. Danesh J., Whincup P., Walker M., et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 103 19 (2001) 2323-2327
33. Lowe G.D., Yarnell J.W., Rumley A., Bainton D., and Sweetnam P.M. C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis?. Arterioscler Thromb Vasc Biol 21 4 (2001) 603-610
34. Robson S.C., Shephard E.G., and Kirsch R.E. Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol 86 2 (1994) 322-326
35. Marenberg M.E., Risch N., Berkman L.F., Floderus B., and de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. New Engl J Med 330 15 (1994) 1041-1046
36. de Lange M., Snieder H., Ariëns R.A., Spector T.D., and Grant P.J. The genetics of haemostasis: a twin study. Lancet 357 9250 (2001) 101-105
37. Mills J.D., Ariëns R.A., Mansfield M.W., and Grant P.J. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 106 15 (2002) 1938-1942
38. Dunn E.J., Ariëns R.A., de Lange M., et al. Genetics of fibrin clot structure: a twin study. Blood 103 5 (2004) 1735-1740
39. Hammar N., Kaprio J., Hagstrom U., Alfredsson L., Koskenvuo M., and Hammar T. Migration and mortality: a 20 year follow up of Finnish twin pairs with migrant co-twins in Sweden. J Epidemiol Community Health 56 5 (2002) 362-366
40. Suefuji H., Ogawa H., Yasue H., et al. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J 134 2 Pt 1 (1997) 253-259
41. Soejima H., Ogawa H., Yasue H., et al. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 99 22 (1999) 2908-2913
42. Ott I., Koch W., von Beckerath N., et al. Tissue factor promotor polymorphism -603 A/G is associated with myocardial infarction. Atherosclerosis 177 1 (2004) 189-191
43. Reny J.L., Laurendeau I., Fontana P., et al. The TF-603A/G gene promoter polymorphism and circulating monocyte tissue factor gene expression in healthy volunteers. Thromb Haemost 91 2 (2004) 248-254
44. Arnaud E., Barbalat V., Nicaud V., Cambien F., Evans A., Morrison C., et al. Polymorphisms in the 5′ regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: the ECTIM and PATHROS studies. Etude Cas-Temoins de l'Infarctus du Myocarde. Paris Thrombosis case-control study. Arterioscler Thromb Vasc Biol 20 3 (2000) 892-898
45. Hedner U. General haemostatic agents - fact or fiction?. Pathophysiol Haemost Thromb 32 Suppl 1 (2002) 33-36
46. Cooper J.A., Miller G.J., Bauer K.A., et al. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation 102 23 (2000) 2816-2822
47. Folsom A.R., Wu K.K., Davis C.E., Conlan M.G., Sorlie P.D., and Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 91 3 (1991) 191-205
48. Heinrich J., Balleisen L., Schulte H., Assmann G., and van de L.J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 14 1 (1994) 54-59
49. Smith F.B., Lee A.J., Fowkes F.G., Price J.F., Rumley A., and Lowe G.D. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery study. Arterioscler Thromb Vasc Biol 17 11 (1997) 3321-3325
50. Voetsch B., and Loscalzo J. Genetic determinants of arterial thrombosis. Arterioscler Thromb Vasc Biol 24 2 (2004) 216-229
51. Iacoviello L., Di Castelnuovo A., de Knijff P., et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. New Engl J Med 338 2 (1998) 79-85
52. Folsom A.R., Wu K.K., Rosamond W.D., Sharrett A.R., and Chambless L.E. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 96 4 (1997) 1102-1108
53. Doggen C.J., Manger C.V., Bertina R.M., Reitsma P.H., Vandenbroucke J.P., et al. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men. Thromb Haemost 80 2 (1998) 281-285
54. van der K., Rosendaal F.R., van der Bom J.G., and Doggen C.J. Polymorphisms in coagulation factors and the risk of recurrent cardiovascular events in men after a first myocardial infarction. J Thromb Haemost 6 5 (2008) 720-725
55. Eriksson-Berg M., Deguchi H., Hawe E., et al. Influence of factor VII gene polymorphisms and environmental factors on plasma coagulation factor VII concentrations in middle-aged women with and without manifest coronary heart disease. Thromb Haemost 93 2 (2005) 351-358
56. Marchetti G., Patracchini P., Papacchini M., Ferrati M., and Bernardi F. A polymorphism in the 5′ region of coagulation factor VII gene (F7) caused by an inserted decanucleotide. Hum Genet 90 5 (1993) 575-576
57. 't Hooft F.M., Silveira A., Tornvall P., et al. Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration. Blood 93 10 (1999) 3432-3441
58. Bernardi F., Arcieri P., Bertina R.M., et al. Contribution of factor VII genotype to activated FVII levels Differences in genotype frequencies between northern and southern European populations. Arterioscler Thromb Vasc Biol 17 11 (1997) 2548-2553
59. Girelli D., Russo C., Ferraresi P., et al. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. New Engl J Med 343 11 (2000) 774-780
60. Carew J.A., Basso F., Miller G.J., et al. A functional haplotype in the 5′ flanking region of the factor VII gene is associated with an increased risk of coronary heart disease. J Thromb Haemost 1 10 (2003) 2179-2185
61. Bozzini C., Girelli D., Bernardi F., et al. Influence of polymorphisms in the factor VII gene promoter on activated factor VII levels and on the risk of myocardial infarction in advanced coronary atherosclerosis. Thromb Haemost 92 3 (2004) 541-549
62. Campo G., Valgimigli M., Ferraresi P., et al. Tissue factor and coagulation factor VII levels during acute myocardial infarction: association with genotype and adverse events. Arterioscler Thromb Vasc Biol 26 12 (2006) 2800-2806
63. Danesh J., Collins R., Appleby P., and Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279 18 (1998) 1477-1482
64. Iacoviello L., Vischetti M., Zito F., and Benedetta D.M. Genes encoding fibrinogen and cardiovascular risk. Hypertension 38 5 (2001) 1199-1203
65. Green F.R. Fibrinogen polymorphisms and atherothrombotic disease. Ann NY Acad Sci 936 (2001) 549-559
66. Grant P.J. The genetics of atherothrombotic disorders: a clinician's view. J Thromb Haemost 1 7 (2003) 1381-1390
67. Reed G.L., and Houng A.K. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism. Circulation 99 2 (1999) 299-304
68. Anwar R., Gallivan L., Edmonds S.D., and Markham A.F. Genotype/phenotype correlations for coagulation factor XIII: specific normal polymorphisms are associated with high or low factor XIII specific activity. Blood 93 3 (1999) 897-905
69. Ariëns R.A., Lai T.S., Weisel J.W., Greenberg C.S., and Grant P.J. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 100 3 (2002) 743-754
70. Lowe G.D., Yarnell J.W., Sweetnam P.M., Rumley A., Thomas H.F., and Elwood P.C. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly study. Thromb Haemost 79 1 (1998) 129-133
71. Cushman M., Lemaitre R.N., Kuller L.H., et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health study. Arterioscler Thromb Vasc Biol 19 3 (1999) 493-498
72. Saigo M., Abe S., Ogawa M., et al. Imbalance of plasminogen activator inhibitor-I/tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction. Thromb Haemost 86 5 (2001) 1197-1203
73. Juhan-Vague I., Pyke S.D., Alessi M.C., Jespersen J., Haverkate F., and Thompson S.G. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT study group European concerted action on thrombosis and disabilities. Circulation 94 9 (1996) 2057-2063
74. Folsom A.R., Aleksic N., Park E., Salomaa V., Juneja H., and Wu K.K. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb Vasc Biol 21 4 (2001) 611-617
75. Hamsten A., de Faire U., Walldius G., et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2 8549 (1987) 3-9
76. Lowe G.D., Danesh J., Lewington S., et al. Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 25 3 (2004) 252-259
77. Nordenhem A., Leander K., Hallqvist J., de Faire U., Sten-Linder M., and Wiman B. The complex between tPA and PAI-1: risk factor for myocardial infarction as studied in the SHEEP project. Thromb Res 116 3 (2005) 223-232
78. Nordenhem A., and Wiman B. Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes. Scand J Clin Lab Invest 58 6 (1998) 475-483
79. Nordt T.K., Lohrmann J., and Bode C. Regulation of PAI-1 expression by genetic polymorphisms Impact on atherogenesis. Thromb Res 103 Suppl 1 (2001) S1-S5
80. Zhan M., Zhou Y., and Han Z.C. No association of the plasminogen activator inhibitor-1 promoter 4G/5G polymorphism with inhibitor level during basal transcription in vitro. Int J Hematol 79 4 (2004) 400-404
81. Hoekstra T., Geleijnse J.M., Schouten E.G., and Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 91 5 (2004) 861-872
82. Humphries S.E., Lane A., Dawson S., and Green F.R. The study of gene-environment interactions that influence thrombosis and fibrinolysis Genetic variation at the loci for factor VII and plasminogen activator inhibitor-1. Arch Pathol Lab Med 116 12 (1992) 1322-1329
83. Iacoviello L., Burzotta F., Di Castelnuovo A., Zito F., Marchioli R., and Donati M.B. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 80 6 (1998) 1029-1030
84. Ludwig M., Wohn K.D., Schleuning W.D., and Olek K. Allelic dimorphism in the human tissue-type plasminogen activator (TPA) gene as a result of an Alu insertion/deletion event. Hum Genet 88 4 (1992) 388-392
85. van der Bom J.G., de Knijff P., Haverkate F., et al. Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam study. Circulation 95 12 (1997) 2623-2627
86. Ridker P.M., Baker M.T., Hennekens C.H., Stampfer M.J., and Vaughan D.E. Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risks of myocardial infarction among middle-aged men. Arterioscler Thromb Vasc Biol 17 9 (1997) 1687-1690
87. Ladenvall P., Johansson L., Jansson J.H., et al. Tissue-type plasminogen activator -7351C/T enhancer polymorphism is associated with a first myocardial infarction. Thromb Haemost 87 1 (2002) 105-109
88. Ladenvall P., Nilsson S., Jood K., Rosengren A., Blomstrand C., and Jern C. Genetic variation at the human tissue-type plasminogen activator (tPA) locus: haplotypes and analysis of association to plasma levels of tPA. Eur J Hum Genet 11 8 (2003) 603-610
89. Fatah K., Silveira A., Tornvall P., Karpe F., Blomback M., and Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 76 4 (1996) 535-540
90. Collet J.P., Park D., Lesty C., et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 20 5 (2000) 1354-1361
91. Ajjan R., Lim B.C., Standeven K.F., et al. Common variation in the C-terminal region of the fibrinogen beta-chain: effects on fibrin structure, fibrinolysis and clot rigidity. Blood 111 2 (2008) 643-650
92. Blombäck B. Fibrinogen structure, activation, polymerization and fibrin gel structure. Thromb Res 75 3 (1994) 327-328
93. Standeven K.F., Grant P.J., Carter A.M., Scheiner T., Weisel J.W., and Ariëns R.A. Functional analysis of the fibrinogen Aa Thr312Ala polymorphism: effects on fibrin structure and function. Circulation 107 18 (2003) 2326-2330
94. Carter A.M., Catto A.J., and Grant P.J. Association of the alpha-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation 99 18 (1999) 2423-2426
95. Carter A.M., Catto A.J., Kohler H.P., Ariëns R.A., Stickland M.H., and Grant P.J. alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism. Blood 96 3 (2000) 1177-1179
96. Suntharalingam J., Goldsmith K., van Marion V., et al. Fibrinogen AalphaThr312Ala polymorphism is associated with Chronic Thromboembolic Pulmonary Hypertension. Eur Respir J 31 4 (2008) 736-741
97. Rasmussen-Torvik L.J., Cushman M., Tsai M.Y., Zhang Y., Heckbert S.R., Rosamond W.D., et al. The association of alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism in the LITE study. Thromb Res 121 1 (2007) 1-7
98. Behague I., Poirier O., Nicaud V., et al. Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM study. Etude Cas-Temoins sur l'Infarctus du Myocarde. Circulation 93 3 (1996) 440-449
99. French J.K., Van de Water N.S., Sutton T.M., et al. Potential thrombophilic mutations/polymorphisms in patients with no flow-limiting stenosis after myocardial infarction. Am Heart J 145 1 (2003) 118-124
100. Carter A.M., Catto A.J., Bamford J.M., and Grant P.J. Gender-specific associations of the fibrinogen B beta 448 polymorphism, fibrinogen levels, and acute cerebrovascular disease. Arterioscler Thromb Vasc Biol 17 3 (1997) 589-594
101. Scrutton M.C., Ross-Murphy S.B., Bennett G.M., Stirling Y., and Meade T.W. Changes in clot deformability - a possible explanation for the epidemiological association between plasma fibrinogen concentration and myocardial infarction. Blood Coagul Fibrinolysis 5 5 (1994) 719-723
102. Standeven K.F., Ariëns R.A., and Grant P.J. The molecular physiology and pathology of fibrin structure/function. Blood Rev 19 5 (2005) 275-288
103. Kobbervig C., and Williams E. FXIII polymorphisms, fibrin clot structure and thrombotic risk. Biophys Chem 112 2-3 (2004) 223-228
104. Shafey M., Anderson J.L., Scarvelis D., Doucette S.P., Gagnon F., and Wells P.S. Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 97 4 (2007) 635-641
105. Ariëns R.A., Philippou H., Nagaswami C., Weisel J.W., Lane D.A., and Grant P.J. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 96 3 (2000) 988-995
106. Bereczky Z., Balogh E., Katona E., et al. Decreased factor XIII levels in factor XIII A subunit Leu34 homozygous patients with coronary artery disease. Thromb Res 121 4 (2008) 469-476
107. Trumbo T.A., and Maurer M.C. Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation. J Biol Chem 275 27 (2000) 20627-20631
108. Marin F., Gonzalez-Conejero R., Lee K.W., et al. A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction. J Am Coll Cardiol 45 1 (2005) 25-29
109. Gonzalez-Conejero R., Fernandez-Cadenas I., Iniesta J.A., et al. Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke 37 9 (2006) 2288-2293
110. Kohler H.P., Mansfield M.W., Clark P.S., and Grant P.J. Interaction between insulin resistance and factor XIII Val34Leu in patients with coronary artery disease. Thromb Haemost 82 3 (1999) 1202-1203
111. Boekholdt S.M., Sandhu M.S., Wareham N.J., Luben R., Reitsma P.H., and Khaw K.T. Fibrinogen plasma levels modify the association between the factor XIII Val34Leu variant and risk of coronary artery disease: the EPIC-Norfolk prospective population study. J Thromb Haemost 4 10 (2006) 2204-2209
112. Bereczky Z., Balogh E., Katona E., et al. Modulation of the risk of coronary sclerosis/myocardial infarction by the interaction between factor XIII subunit A Val34Leu polymorphism and fibrinogen concentration in the high risk Hungarian population. Thromb Res 120 4 (2007) 567-573
113. Lim B.C., Ariens R.A., Carter A.M., Weisel J.W., and Grant P.J. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 361 9367 (2003) 1424-1431
114. Wells P.S., Anderson J.L., Scarvelis D.K., Doucette S.P., and Gagnon F. Factor XIII Val34Leu variant is protective against venous thromboembolism: a HuGE review and meta-analysis. Am J Epidemiol 164 2 (2006) 101-109
115. Pieters M., Covic N., van der Westhuizen F.H., et al. Glycaemic control improves fibrin network characteristics in type 2 diabetes - a purified fibrinogen model. Thromb Haemost 99 4 (2008) 691-700
116. Jörneskog G., Egberg N., Fagrell B., et al. Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia 39 12 (1996) 1519-1523
117. Cubbon R.M., Wheatcroft S.B., Grant P.J., et al. Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003. Eur Heart J 28 5 (2007) 540-545
118. Sambola A., Osende J., Hathcock J., et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 107 7 (2003) 973-977
119. Meade T.W., North W.R., Chakrabarti R., et al. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1 8177 (1980) 1050-1054
120. Hammer M.R., John P.N., Flynn M.D., Bellingham A.J., and Leslie R.D. Glycated fibrinogen: a new index of short-term diabetic control. Ann Clin Biochem 26 Pt 1 (1989) 58-62
121. Dunn E.J., and Ariëns R.A. Fibrinogen and fibrin clot structure in diabetes. Herz 29 5 (2004) 470-479
122. Dunn E.J., Ariëns R.A., and Grant P.J. The influence of type 2 diabetes on fibrin structure and function. Diabetologia 48 6 (2005) 1198-1206
123. Dunn E.J., Philippou H., Ariëns R.A., and Grant P.J. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 49 5 (2006) 1071-1080
124. Pieters M., Covic N., Loots du T., et al. The effect of glycaemic control on fibrin network structure of type 2 diabetic subjects. Thromb Haemost 96 5 (2006) 623-629
125. Mansfield M.W., Stickland M.H., and Grant P.J. PAI-1 concentrations in first-degree relatives of patients with non-insulin-dependent diabetes: metabolic and genetic associations. Thromb Haemost 77 2 (1997) 357-361
126. Carvalho de Sousa J., Bruckert E., Giral P., et al. Coagulation factor VII and plasma triglycerides Decreased catabolism as a possible mechanism of factor VII hyperactivity. Haemostasis 19 3 (1989) 125-130
127. Simpson H.C., Mann J.I., Meade T.W., Chakrabarti R., Stirling Y., and Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet 1 8328 (1983) 786-790
128. Iso H., Shimamoto T., Sato S., Koike K., Iida M., and Komachi Y. Passive smoking and plasma fibrinogen concentrations. Am J Epidemiol 144 12 (1996) 1151-1154
129. Ariëns R.A., Kohler H.P., Mansfield M.W., and Grant P.J. Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals Relation to sex, age, smoking, and hypertension. Arterioscler Thromb Vasc Biol 19 8 (1999) 2012-2016
130. Mansfield M.W., Kohler H.P., Ariëns R.A., McCormack L.J., and Grant P.J. Circulating levels of coagulation factor XIII in subjects with type 2 diabetes and in their first-degree relatives. Diabetes Care 23 5 (2000) 703-705
131. Sasaki A., Kurisu A., Ohno M., and Ikeda Y. Overweight/obesity, smoking, and heavy alcohol consumption are important determinants of plasma PAI-1 levels in healthy men. Am J Med Sci 322 1 (2001) 19-23
132. Yarnell J.W., Sweetnam P.M., Rumley A., and Lowe G.D. Lifestyle and hemostatic risk factors for ischemic heart disease: the Caerphilly study. Arterioscler Thromb Vasc Biol 20 1 (2000) 271-279
133. Dunstan D.W., Mori T.A., Puddey I.B., et al. A randomised, controlled study of the effects of aerobic exercise and dietary fish on coagulation and fibrinolytic factors in type 2 diabetics. Thromb Haemost 81 3 (1999) 367-372
134. Peetz D., Victor A., Adams P., et al. Genetic and environmental influences on the fibrinolytic system: a twin study. Thromb Haemost 92 2 (2004) 344-351
135. De Pergola G., and Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest 25 10 (2002) 899-904
136. Lee K.W., and Lip G.Y. Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review. Arch Intern Med 163 19 (2003) 2368-2392
137. de Gaetano G., Di Castelnuovo A., Donati M.B., and Iacoviello L. The mediterranean lecture: wine and thrombosis - from epidemiology to physiology and back. Pathophysiol Haemost Thromb 33 5-6 (2003) 466-471
138. de Maat M.P. Effects of diet, drugs, and genes on plasma fibrinogen levels. Ann NY Acad Sci 936 (2001) 509-521
139. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 24 11 (2004) 1980-1987
140. Bjornsson T.D., Schneider D.E., and Berger Jr. H. Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther 250 1 (1989) 154-161
141. Henschen-Edman A.H. Fibrinogen non-inherited heterogeneity and its relationship to function in health and disease. Ann NY Acad Sci 936 (2001) 580-593
142. He S., Blombäck M., Yoo G., Sinha R., and Henschen-Edman A.H. Modified clotting properties of fibrinogen in the presence of acetylsalicylic acid in a purified system. Ann NY Acad Sci 936 (2001) 531-535
143. Undas A., Sydor W.J., Brummel K., Musial J., Mann K.G., and Szczeklik A. Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism. Circulation 107 1 (2003) 17-20
144. Mazoyer E., Ripoll L., Boisseau M.R., and Drouet L. How does ticlopidine treatment lower plasma fibrinogen?. Thromb Res 75 3 (1994) 361-370
145. Woodward M., Lowe G.D., Francis L.M., Rumley A., and Cobbe S.M. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J Thromb Haemost 2 11 (2004) 1934-1940
146. Schmidt-Ott K.M., Kagiyama S., and Phillips M.I. The multiple actions of angiotensin II in atherosclerosis. Regul Pept 93 1-3 (2000) 65-77
147. Rosenson R.S. Modulating atherosclerosis through inhibition or blockade of angiotensin. Clin Cardiol 26 7 (2003) 305-311
148. Cooper M.E. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens 17 11 Pt 2 (2004) 16S-20S
149. Fogari R., Zoppi A., Lazzari P., et al. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol 32 4 (1998) 616-620
150. Makris T.K., Stavroulakis G.A., Krespi P.G., et al. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am J Hypertens 13 7 (2000) 783-788
151. Makris T.K., Stavroulakis G., Papadopoulos D.P., et al. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan. Drugs Exp Clin Res 30 3 (2004) 125-132
152. Fogari R., Mugellini A., Zoppi A., et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens 15 4 Pt 1 (2002) 316-320
153. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 89 4 (2003) 601-609
154. Gotto Jr. A.M. Statins, cardiovascular disease, and drug safety. Am J Cardiol 97 8A (2006) 3C-5C
155. Sukhova G.K., Williams J.K., and Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 22 9 (2002) 1452-1458
156. Luan Z., Chase A.J., and Newby A.C. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 23 5 (2003) 769-775
157. Hakamada-Taguchi R., Uehara Y., et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res 93 10 (2003) 948-956
158. Rosenson R.S. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 173 1 (2004) 1-12
159. Juhan-Vague I., Valadier J., Alessi M.C., et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 57 1 (1987) 67-72
160. Porreca E., Di Febbo C., Amore C., et al. Effect of lipid-lowering treatment on factor VII profile in hyperlipidemic patients. Thromb Haemost 84 5 (2000) 789-793
161. Undas A., Brummel K.E., Musial J., Mann K.G., and Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 103 18 (2001) 2248-2253
162. Eto M., Kozai T., Cosentino F., Joch H., and Luscher T.F. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 105 15 (2002) 1756-1759
163. Tekin A., Tekin G., Guzelsoy D., et al. Effects of atorvastatin (10 mg) on hemostatic and inflammatory parameters in hyperlipidemic patients with angiographically proven coronary artery disease. Am J Cardiol 94 2 (2004) 206-209
164. Masamura K., Oida K., Kanehara H., et al. Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol 23 3 (2003) 512-517
165. Neve B.P., Corseaux D., Chinetti G., et al. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 103 2 (2001) 207-212
166. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 18 5 (2002) 269-276
167. Kockx M., Gervois P.P., Poulain P., et al. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. Blood 93 9 (1999) 2991-2998
168. Okopien B., Cwalina L., Lebek M., et al. Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia. Int J Clin Pharmacol Ther 39 12 (2001) 551-557
169. Grant PJ. Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab 2003;29(4 Pt 2):6S44-52.
170. Charles M.A., Morange P., Eschwege E., Andre P., Vague P., and Juhan-Vague I. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study Biguanides and the Prevention of the Risk of Obesity. Diabetes Care 21 11 (1998) 1967-1972
171. Standeven K.F., Ariëns R.A., Whitaker P., Ashcroft A.E., Weisel J.W., and Grant P.J. The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes 51 1 (2002) 189-197
172. Dhall D.P., and Nair C.H. Effects of gliclazide on fibrin network. J Diabetes Complication 8 4 (1994) 231-234
173. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 9131 (1998) 854-865
174. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New Engl J Med 356 24 (2007) 2457-2471
175. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 9493 (2005) 1279-1289
176. Staels B. PPARgamma and atherosclerosis. Curr Med Res Opin 21 Suppl 1 (2005) S13-S20
177. Chinetti G., Lestavel S., Bocher V., et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7 1 (2001) 53-58
178. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., and Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 6 (2002) 679-684
179. Li D., Chen K., Sinha N., Zhang X., et al. The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res 65 4 (2005) 907-912
180. Derosa G., Cicero A.F., Gaddi A., et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 69 1 (2005) 5-13
181. Allahtavakoli M., Shabanzadeh A., Roohbakhsh A., and Pourshanazari A. Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats. Basic Clin Pharmacol Toxicol 101 5 (2007) 309-314
182. Schwarz U.I., Ritchie M.D., Bradford Y., Li C., Dudek S.M., Frye-Anderson A., et al. Genetic determinants of response to warfarin during initial anticoagulation. New Engl J Med 358 10 (2008) 999-1008
183. Shurin S.B., and Nabel E.G. Pharmacogenomics - ready for prime time?. New Engl J Med 358 10 (2008) 1061-1063